Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential versus simultaneous PCV13 and PPV23 vaccination in unvaccinated older adults
2014-004013-85Phase 4Completed
- Sponsor
- Friedrich Schiller University Jena
- Start
- Nov 2015
- Modality
- Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4 trial of pneumococcal 13-valent conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal disease (2 arms), sponsored by Friedrich Schiller University Jena. Primary endpoint: Change in pneumococcal-specific memory B-cell immune response at 27-28 weeks. Started Nov 2015; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccine23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2014-004013-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004013-85.